MENU

CLLS Stock Tickeron detected bullish Stock Pattern: Head-and-Shoulders Bottom CLLS on November 25, 2024, netting in a 13.90% gain over 1 month

A.I.dvisor
at Tickeron.com
Loading...
+13.90% Gain from a Successful pattern Head-and-Shoulders Bottom
CLLS - Cellectis SA
Tickeron
Ticker: CLLS
Company: Cellectis SA
Gain: +13.9%
Confirmed: 11/25/24
Succeeded: 01/06/25
Total length: 52 days
On November 15, 2024, A.I.dvisor detected a Head-and-Shoulders Bottom Pattern (Bullish) for Cellectis SA (CLLS, $1.87). On November 25, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $2.20. 42 days later, on January 06, 2025, CLLS reached the target price resulting in a +1 for traders who took a long position in the stock.

CLLS's Stochastic Oscillator is staying in oversold zone for 9 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CLLS turned negative on January 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

CLLS moved below its 50-day moving average on January 13, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on January 15, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLLS broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CLLS entered a downward trend on January 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.176) is normal, around the industry mean (15.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.784). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.848). CLLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.279) is also within normal values, averaging (276.027).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com